Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFF269 in Healthy Volunteers and Hypertension Patients
NCT02047656Phase 1Terminated
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LFF269 in hypertension (HTN), sponsored by Novartis. Primary endpoint: Number of healthy volunteers reported with adverse events at 10 days. Started Aug 2013; status: terminated.
02
Drugs
LFF269
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02047656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047656.